BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M, Hodivala-Dilke K, Capasso M, Kocher HM. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. Cell Mol Gastroenterol Hepatol 2021;12:1543-65. [PMID: 34252585 DOI: 10.1016/j.jcmgh.2021.06.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
2 Singh A, Beechinor RJ, Huynh JC, Li D, Dayyani F, Valerin JB, Hendifar A, Gong J, Cho M. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2164. [PMID: 33946408 DOI: 10.3390/cancers13092164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Aloj L, Giger O, Mendichovszky IA, Challis BG, Ronel M, Harper I, Cheow H, Hoopen RT, Pitfield D, Gallagher FA, Attili B, McLean M, Jones RL, Dileo P, Bulusu VR, Maher ER, Casey RT. The role of [68 Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST). EJNMMI Res 2021;11:5. [PMID: 33443647 DOI: 10.1186/s13550-021-00747-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 19.0] [Reference Citation Analysis]
5 Liu X, Wang G, Yan X, Qiu H, Min P, Wu M, Tang C, Zhang F, Tang Q, Zhu S, Qiu M, Zhuang W, Fang DD, Zhou Z, Yang D, Zhai Y. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019;9:88. [PMID: 31673329 DOI: 10.1186/s13578-019-0351-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pluschnig U. Cure in metastatic disease: how to manage and who is the right patient in GIST. memo 2018;11:180-184. [DOI: 10.1007/s12254-018-0432-y] [Reference Citation Analysis]
7 Liu LM, Xiong DD, Lin P, Yang H, Dang YW, Chen G. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. Int J Oncol 2018;53:1897-912. [PMID: 30132517 DOI: 10.3892/ijo.2018.4531] [Cited by in Crossref: 13] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
8 Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, Feng ZB, Chen G. A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med 2018;16:220. [PMID: 30092792 DOI: 10.1186/s12967-018-1593-5] [Cited by in Crossref: 147] [Cited by in F6Publishing: 159] [Article Influence: 29.4] [Reference Citation Analysis]